

RESOLUTION

Subject: HPV Vaccination until age 45

Submitted by: Monalisa Tailor, MD

Referred to: Reference Committee

WHEREAS, human papillomavirus (HPV) is a common sexually transmitted infection associated with multiple cancers, including cervical, oropharyngeal, anal, penile, vulvar, and vaginal cancers; and

WHEREAS, HPV vaccination is a safe and effective preventive measure that significantly reduces the incidence of HPV-related infections, precancerous lesions, and cancers; and

WHEREAS, the U.S. Food and Drug Administration has approved HPV vaccination for individuals up to age 45; and

WHEREAS, the Advisory Committee on Immunization Practices (ACIP) recommends shared clinical decision-making regarding HPV vaccination for adults aged 27 through 45 who are not adequately vaccinated; and

WHEREAS, many adults aged 27–45 remain unvaccinated and may still be at risk for new HPV infections, particularly with new sexual partners or other risk factors; and

WHEREAS, expanding awareness and support for HPV vaccination in this age group may help reduce the burden of HPV-related cancers and improve public health outcomes; now, therefore, be it

RESOLVED, that KMA supports human papillomavirus (HPV) vaccination for eligible adults up to age 45, consistent with U.S. Food and Drug Administration (FDA) approval and Advisory Committee on Immunization Practices (ACIP) (Pre May 2025) shared clinical decision-making recommendations; and be it further

RESOLVED, that KMA encourages physicians to engage in informed discussions with patients regarding the risks and benefits of HPV vaccination; and be it further

RESOLVED, that KMA supports efforts to improve access to HPV vaccination for adults up to age 45, including insurance coverage and public health initiatives; and be it further

RESOLVED, that KMA promotes education and awareness campaigns to increase understanding of HPV-related cancer prevention across all eligible age groups.